Myasthenia Gravis
Welcome,         Profile    Billing    Logout  
 64 Companies   21 Products   21 Products   23 Mechanisms of Action   207 Trials   10745 News 


«12...345678910111213...136137»
  • ||||||||||  CoronaVac / Sinovac, Bio Farma Indonesia, Comirnaty (tozinameran) / Pfizer, BioNTech
    Journal:  Evaluation of Clinical Effects of COVID-19 Infection and Vaccines on Myasthenia Gravis. (Pubmed Central) -  Sep 11, 2024   
    Of the patients, 96(68%) received at least one dose BNT162b2 or CoronaVac, while 30.4% of the patients received ?3 doses of vaccines...Our study results suggest that COVID-19 infection affects MG similar to the general population and does not lead to worsening MG symptoms. Both mRNA and inactivated vaccines with proven efficacy can be used safely in MG patients.
  • ||||||||||  UNVEILING FATIGUE: MYASTHENIA GRAVIS VS HYPERSOMNIA: A CRUCIAL DISTINCTION (Convention Center Exhibit Hall: Poster Area 5) -  Sep 11, 2024 - Abstract #CHEST2024CHEST_7101;    
    Given the vast array of causes that can lead to hypersomnia, it can be easy to become hyper-focused on the more common sleep medicine diagnoses. Due to the commonality of fatigue in both sleep and neuromuscular disorders, this case represents essential considerations that must be made to improve patient outcomes.
  • ||||||||||  itraconazole / Generic mfg.
    UNMASKING THE SILENT INVADER: NAVIGATING DISSEMINATED HISTOPLASMOSIS PRESENTING AS CUTANEOUS AND LYMPH NODE INVOLVEMENT (Convention Center Exhibit Hall: Rapid Fire Area 1D) -  Sep 11, 2024 - Abstract #CHEST2024CHEST_7050;    
    Early recognition of the infection and a multidisciplinary approach involving dermatology, infectious disease, and internal medicine specialists, led to timely intervention and improved clinical outcomes. The utilization of Itraconazole, considering the patient's overall health status, exemplifies the tailored approach required in managing fungal infections in the elderly.
  • ||||||||||  ampicillin/sulbactam / Generic mfg., methamphetamine / Generic mfg.
    CAT GOT YOUR TONGUE? A CASE OF PASTEURELLA MULTOCIDA-ASSOCIATED MILLER FISHER SYNDROME (Convention Center Exhibit Hall: Rapid Fire Area 3D) -  Sep 11, 2024 - Abstract #CHEST2024CHEST_6919;    
    Incidentally, she was also discovered to have used 3,4-methylenedioxy-methamphetamine (MDMA) around this timeline...Antibiotics were narrowed and she received 5 days of ampicillin-sulbactam... In summary, MFS is a rare and aggressive form of GBS, and even more rarely may be associated with P multicoda associated infection.
  • ||||||||||  Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
    CYTOMEGALOVIRUS-INDUCED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH) IN A CRITICALLY ILL PATIENT WITH PSORIATIC ARTHRITIS (Convention Center Exhibit Hall: Poster Area 2) -  Sep 11, 2024 - Abstract #CHEST2024CHEST_6553;    
    This case highlights the importance of including HLH on the differential in patients with spondyloarthropathies especially those who are chronically immunosuppressed, who present with pancytopenia and nonspecific symptoms. Early initiation of HLH workup and, if appropriate, empiric treatment, has the potential to reduce mortality in this rare but potentially fatal condition.
  • ||||||||||  Review, Journal:  Ocular myasthenia gravis (Pubmed Central) -  Sep 10, 2024   
    Specialists often encounter challenges in diagnosing this form, as serological and electrophysiological studies may be uninformative, necessitating diagnosis based on patient history and clinical picture. This literature review outlines the key aspects of the pathogenesis, clinical manifestations, methods of diagnosis and treatment of ocular myasthenia gravis.
  • ||||||||||  Rituxan (rituximab) / Roche
    Biomarker, Retrospective data, Journal:  Serological Markers of Clinical Improvement in MuSK Myasthenia Gravis. (Pubmed Central) -  Sep 9, 2024   
    Our data support the quantification of MuSK antibodies by flow cytometry. Through a multimodal investigational approach, we showed that total MuSK-IgG levels, MuSK-IgG4 and MuSK-IgG2 levels, and MuSK-IgG affinity may represent promising biomarkers of disease outcomes in MuSK-MG.
  • ||||||||||  Journal:  Rectal cancer with solitary hepatic metastasis and Lambert-Eaton myasthenic syndrome. (Pubmed Central) -  Sep 5, 2024   
    There are few concerned reports on Gastrointestinal carcinomas. This article reports the treatment process of a young woman with rectal cancer and liver metastasis who associated with LEMS to summarize relevant clinical experience and reduce the rate of clinical misdiagnosis.
  • ||||||||||  Retrospective data, Review, Journal:  Myasthenia Gravis and COVID-19: A Systematic Review and Meta-analysis. (Pubmed Central) -  Sep 4, 2024   
    Additionally, the pooled prevalence of hospitalization among those with COVID-19 infection was 43% (95% CI, 26%, 60%; I2=97.6%; P<0.001), and the pooled prevalence of MG exacerbation was 33% (95% CI, 20%, 46%; I2=92.6%; P<0.001). In summary, this systematic review and meta-analysis reveal that the pooled prevalence of COVID-19 infection in individuals with MG is 2%.
  • ||||||||||  prednisone / Generic mfg.
    Biomarker, Retrospective data, Journal:  Predictive Factors for Poor Outcomes Associated with COVID-19 in a Retrospective Cohort of Myasthenia Gravis Patients. (Pubmed Central) -  Sep 3, 2024   
    Prednisone or immunosuppressant treatment had the potential to reduce the occurrence of poor outcomes, while the duration of prednisone or immunosuppressant usage was associated with a higher risk of poor outcomes...The risk of poor outcomes was reduced in patients controlled by short-term immunosuppressive therapy. Novel coronavirus might affect inflammatory and immune responses in MG patients, particularly in altering interleukin-6 and regulatory T cell levels.
  • ||||||||||  Journal:  Congenital myasthenic syndromes: increasingly complex. (Pubmed Central) -  Sep 3, 2024   
    Given the widening nonneuromuscular junction phenotypes in the newly identified forms of CMS, new therapies need to include disease-modifying approaches that address not only neuromuscular weakness but also the multisystem involvement. Whilst the current treatments for CMS are highly effective for many subtypes there remains, in a proportion of CMS patients, an unmet need for more efficacious therapies.
  • ||||||||||  Cardiac Sarcoidosis Associated With TNF-alpha Inhibition: Report Of Two Cases. (Exhibit Hall C - ePoster Hub; Monitor 17) -  Sep 3, 2024 - Abstract #HFSA2024HFSA_410;    
    inhibitors like infliximab and adalimumab have also been reported to be effective for the treatment of sarcoidosis associated with etanercept. Further studies are necessary to elucidate the exact mechanisms that underlie the pathophysiology of sarcoidosis associated with etanercept and CZP, and the optimal therapies for these patients.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Review, Journal:  The efficacy and safety of eculizumab in patients and the role of C5 polymorphisms. (Pubmed Central) -  Sep 2, 2024   
    Genetic sequencing revealed three distinct C5 mutations in the non-responders and these polymorphisms appeared to be most prevalent among Japanese, Korean and African populations. Here, we present an overview of the current and potential future applications of eculizumab, as well as the disadvantages of eculizumab treatment in patients with C5 polymorphisms.
  • ||||||||||  Journal:  Sleep in Myasthenia Gravis: A Questionnaire-Based Study. (Pubmed Central) -  Sep 2, 2024   
    Patients of MG with stable clinical course with adequate treatment have sleep quality comparable with healthy controls. Longitudinal assessment of sleep quality at multiple time points throughout the disease course and correlating with cross-sectional disease severity may further delineate the impact of disease on sleep and QoL.
  • ||||||||||  mycophenolate mofetil / Generic mfg., azathioprine / Generic mfg.
    Journal:  Effectiveness and Safety of Mycophenolate Mophetil in Myasthenia Gravis: A Real-Life Multicenter Experience. (Pubmed Central) -  Aug 31, 2024   
    Conversely, results showed that MMF is effective and well-tolerated in the long-term management of MG, providing faster symptom control and a favorable safety profile. Future prospective studies with larger cohorts are needed to confirm these findings and explore sex differences in response to MMF treatment.
  • ||||||||||  Journal:  Insights from CD71 presentation and serum lipid peroxidation in myasthenia gravis - A small cohort study. (Pubmed Central) -  Aug 31, 2024   
    These results suggest a possible relationship between iron metabolism, levels of CD71-expressing cells, and lipid peroxidation in MG. Conversely, pyridostigmine treatment reduced the levels of CD71-expressing cells and lipid peroxidation, suggesting potential immunomodulatory and antioxidant impacts of pyridostigmine in MG, either directly or indirectly.
  • ||||||||||  Journal:  Structural switch in acetylcholine receptors in developing muscle. (Pubmed Central) -  Aug 31, 2024   
    We find that ACh affinity differences are driven by binding site access, channel conductance is tuned by widespread surface electrostatics and open duration changes result from intrasubunit interactions and structural flexibility. The structures further reveal pathogenic mechanisms underlying congenital myasthenic syndromes.
  • ||||||||||  Journal:  Decoding Multiple Antibody Positivity: Lessons from Paraneoplastic Sensory Ataxia. (Pubmed Central) -  Aug 28, 2024   
    We report a rare case of sensory neuronopathy with triple paraneoplastic antibody positivity (anti-Hu, anti-collapsing response-mediator protein 5, and anti-amphiphysin) on immunoblot but only anti-Hu positivity on immunofluorescence. The presence of lower facial dyskinesias should raise the possibility of an immune-mediated neurologic syndrome in the appropriate clinical context.
  • ||||||||||  Ultomiris (ravulizumab-cwvz) / AstraZeneca
    Enrollment open, Enrollment change, Trial initiation date:  Study of Ultomiris (clinicaltrials.gov) -  Aug 27, 2024   
    P=N/A,  N=75, Recruiting, 
    Our findings could help partially clarify the pathophysiology of TAMG, which could be new potential targets for subsequent clinical immunotherapy. Not yet recruiting --> Recruiting | N=300 --> 75 | Initiation date: Mar 2024 --> Sep 2024
  • ||||||||||  Review, Journal, CAR T-Cell Therapy:  Advancements and challenges in CAR T cell therapy in autoimmune diseases. (Pubmed Central) -  Aug 27, 2024   
    In this Review, we discuss important aspects of CAR T cell therapy in autoimmune disease, including considerations relating to patient selection, safety, efficacy and medical management. These considerations are based on the early experiences of CAR T cell therapy in autoimmune diseases, and as the field of CAR T cell therapy in autoimmune diseases continues to rapidly evolve, these issues will remain subject to ongoing refinement and adaptation.
  • ||||||||||  atorvastatin / Generic mfg.
    Journal:  Worsening of myasthenic symptoms associated with statins. (Pubmed Central) -  Aug 26, 2024   
    Regarding statin-associated myasthenic worsening, prevalence was low, and severity was mild; with cessation of statin use, symptoms improved within a few months, and outcomes were generally good. Although statins can be used in MG patients with little concern, statin-associated myasthenic worsening should be noted in addition to the classical statin intolerance associated with statin use.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Journal:  Experience of using eculizumab in refractory myasthenia gravis (Pubmed Central) -  Aug 23, 2024   
    Based on the results of randomized controlled trials, data on the effectiveness and safety of eculizumab, which inhibits the C5 component of the complement system, is presented. We present our own clinical experience of using eculizumab in a young woman with refractory generalized AChR-positive MG with a rapid decrease in the severity of symptoms to a minimum level and restoration of ability to work, and the absence of adverse events during therapy.
  • ||||||||||  Vyvgart (efgartigimod alfa-fcab) / argenx, Broteio
    Journal:  Efgartigimod combined with steroids as a fast-acting therapy for myasthenic crisis: a case report. (Pubmed Central) -  Aug 23, 2024   
    Our case suggests that efgartigimod can be an alternative drug for achieving minimal manifestation status in patients with myasthenic crisis. Considering its strong efficacy and safety, efgartigimod could be expanded to use as bridging therapy in the acute and chronic phases of gMG.
  • ||||||||||  Review, Journal:  Congenital myasthenic syndromes. (Pubmed Central) -  Aug 23, 2024   
    Subsequently, it became clear that myasthenic syndromes also stem from mutations in proteins involved in neurotransmitter release, the formation and maintenance of the neuromuscular synapse, or glycosylation. This chapter describes the patient phenotypes, the diverse range of molecular mechanisms for synaptic dysfunction, and the corresponding therapeutic strategies, including drug combinations, that can be tailored to the many subtypes.
  • ||||||||||  Review, Journal:  Neuromyotonia. (Pubmed Central) -  Aug 23, 2024   
    In cases in which there is evidence for an immune cause, then immune suppression, with an emerging role for B cell-depleting therapies, is associated with a good clinical outcome. In parallel, sodium channel blocking drugs remain effective symptomatic therapies.
  • ||||||||||  Review, Journal:  Myasthenia gravis. (Pubmed Central) -  Aug 23, 2024   
    A growing number of therapies are available for both acute and chronic management of MG, with several new mechanistic approaches under investigation. An international consensus guidance for the management of MG was first published in 2016 and updated in 2020.
  • ||||||||||  Phenotyping of a quick passive transfer model of myasthenia gravis (MCP Hall A) -  Aug 22, 2024 - Abstract #Neuroscience2024Neuroscience_2186;    
    The reduction in this group was 11.5% at 5 Hz, 11.8% at 10 Hz and 11.6% at 20 Hz whereas there was a slight increase in the amplitude in the sham and mAb35 lower dose groups.In conclusion, the 1 mg/kg mAb35 dose resulted in rapidly progressing and severe myasthenia gravis-like disease with evident muscle fatiguability that can be utilized to test the effects of potential therapies e.g., targeting the autoantibodies, the complement or making the AChR more available in the NMJ. Lower mAb35 doses did not lead to a significant disease phenotype suggesting an
  • ||||||||||  ITIH3: a serum biomarker for disease activity in myasthenia gravis (MCP Hall A) -  Aug 22, 2024 - Abstract #Neuroscience2024Neuroscience_2184;    
    Immunoprecipitation of ITH3 lead to identification of its interaction partners playing crucial roles in neuromuscular transmission.This study provides data on ITIH3 as a potential pathophysiological-relevant biomarker of disease activity in myasthenia gravis. Future studies are required to facilitate translation into clinical practice.